Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Written by: | no-reply@reuters.com | Dated: Monday, May 13th, 2019

 

ZURICH (Reuters) – Novartis on Monday said claims of price fixing against its Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.

“We believe that these claims are without merit and will vigorously contest them,” Novartis said. “Sandoz takes its obligations under the antitrust laws seriously. We will continue to be committed to providing high-quality, affordable medicines to U.S. patients, and conducting business with customers and the government with integrity.”

The 500-page lawsuit, filed by U.S. states on Friday, contends drugmakers conspired to inflate drug prices, sometimes by more than 1,000% or more, as well as stifle competition.

 

Reporting by John Miller; Editing by Michael Shields

 

Reuters source:

https://www.reuters.com/article/us-usa-drugs-lawsuit-novartis/novartis-vows-to-fight-u-s-price-fixing-claims-against-sandoz-unit-idUSKCN1SJ0U6

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom